

**CANCER RESEARCH  
ONCOLOGY CLINICAL TRIALS**

**BREAST**

<b>PACCT-1 TAILORx</b>	<b>Program for the Assessment of Clinical Cancer Tests (PACCT-1): <i>Trial Assigning Individualized Options for Treatment: The TAILORx Trial</i></b>	<b>1</b>
<b>SWOG S0307</b>	<b>Phase III Trial of Biphosphonates as Adjuvant Therapy for Primary Breast Cancer</b>	<b>2</b>
<b>NSABP B-42</b>	<b>A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer</b>	<b>3</b>
<b>IBCSG 24-02</b>	<b>Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer; Suppression of Ovarian Function Trial (SOFT): Tamoxifen versus Ovarian function suppression + tamoxifen versus Ovarian function suppression + exemestane</b>	<b>4</b>
<b>N063D ALTTO</b>	<b>A Randomized, Multi-centre, Open label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer</b>	<b>5</b>
<b>SWOG 0500</b>	<b>A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment</b>	<b>6</b>
<b>SWOG S0226</b>	<b>A Phase III Randomized Trial of Anastrozole vs Anastrozole and Fulvestrant as First Line Therapy for Post-Menopausal Women w/Metastatic Breast Ca</b>	<b>7</b>
<b>C 40302</b>	<b>Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer</b>	<b>8</b>
<b>E-5103</b>	<b>A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer</b>	<b>9</b>
<b>VIRGO AVF 4349n</b>	<b>An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer</b>	<b>10</b>
<b>N 0733</b>	<b>Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Pts with HER2 + Breast ca Previously treated with Trastuzumab and an Anthracycline and/or a Taxane</b>	<b>11</b>

*For information about the studies or for obtaining the protocol, please call the Research  
Office at (818) 409-7653*

**CANCER RESEARCH  
ONCOLOGY CLINICAL TRIALS**

**LUNG**

<b>SWOG E5597</b>	<b>Phase III Chemoprevention Trial of Selenium Supplementation in persons with resected Stage I (T1) NSCLC</b>	<b>12</b>
<b>SWOG 0424</b>	<b>Epidemiology Study: Collection of Tissue, Blood, and QOL for Stage I, II, and III Lung cancer, Males and Females Smoking strata enrollment complete</b>	<b>13</b>
<b>ECOG 1505</b>	<b>A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)</b>	<b>14</b>

**GI: COLON /RECTUM**

<b>NSABP R-04</b>	<b>Preoperative XRT + Capecitabine vs. Preoperative XRT +Continuous Infusion 5-Fluorouracil (5FU) in PTs with Operable Carcinoma of the Rectum</b>	<b>15</b>
<b>ECOG 5202</b>	<b>A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (T3-T4-NO w/@least 8 LNs removed)</b>	<b>16</b>
<b>E 5204</b>	<b>Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or Stage III Rectal Cancer Receiving Pre-operative Chemoradiation</b>	<b>17</b>
<b>CALGB 80101</b>	<b>PHASE III Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adeno Ca</b>	<b>18</b>
<b>CALGB 80405</b>	<b>Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin w/Bevacizumab or Cetuximab (C225) for Patients w/Untreated Metastatic Adeno CA of the Colon or Rectum</b>	<b>19</b>
<b>S 0600</b>	<b>Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as <u>Second-Line Therapy</u> for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX</b>	<b>20</b>

**GU:**

<b>S 0421</b>	<b>Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Pts with Advanced Hormone Refractory Prostate Cancer</b>	<b>21</b>
<b>E 2804</b>	<b>The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Tosirolimus in Advanced Renal Cell Carcinoma</b>	<b>22</b>

*For information about the studies or for obtaining the protocol, please call the Research Office at (818) 409-7653*

**CANCER RESEARCH  
ONCOLOGY CLINICAL TRIALS**

**Multiple Myeloma/ AML**

<b>MM C05009</b>	<b>Randomized Phase IIB Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE® and Dexamethasone (VD) versus VELCADE®, Melphalan, and Prednisone (VMP)</b>	<b>23</b>
<b>AML</b>	<b>Seattle Genetics: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60Years of Age and Older with Previously Untreated AML</b>	<b>24</b>

*For information about the studies or for obtaining the protocol, please call the Research  
Office at (818) 409-7653*